The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and HighfineZhitong·Oct 29, 2025 at 12:15 AM301230+8.38%300347+1.96%
Jiuzhou Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 748 million yuan, a year-on-year increase of 18.51%Zhitong·Oct 15, 2025 at 03:36 AM603456+1.25%
CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit upZhitong·Sep 24, 2025 at 08:55 PM000739+1.00%603456+1.25%
Jiuzhou Pharma's subsidiary Ruibo Suzhou passes on-site inspection by the U.S. FDAZhitong·Aug 12, 2025 at 02:41 AM603456+1.25%
Cinda Securities: Jiuzhou Pharma's DMO business maintains high growth, and the layout of new molecular business is expected to create new growth pointsZhitong·Aug 8, 2025 at 01:37 AM603456+1.25%
28 stocks received buy ratings from brokerages, with Jiuzhou Pharma's target increase reaching 57.75%Zhitong·Aug 6, 2025 at 07:33 PM002891+2.24%603456+1.25%
The social security fund appears among the top ten circulating shareholders of three stocks, with a total holding market value of 282 million yuanZhitong·Aug 5, 2025 at 08:03 PM000404+1.69%603508+0.70%
Jiuzhou Pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 526 million yuan, an increase of 10.70%Zhitong·Aug 5, 2025 at 03:15 AM603456+1.25%
Guotai Junan Securities: The overall CXO investment and financing is showing a warming trend, focusing on investment opportunities in the new molecular industrial chainZhitong·Aug 4, 2025 at 12:52 AM603456+1.25%300759+2.19%
CRO/CMO concept experiences a volatile surge, ChemPartner hits the "20cm" limit upZhitong·Jul 29, 2025 at 12:34 AM603456+1.25%300347+1.96%
CRO concept stocks fluctuate and rise, PHARMABLOCK increases by over 10%Zhitong·Jul 28, 2025 at 09:26 PM300725+2.29%603456+1.25%
Jiuzhou Pharma: Dapagliflozin has received approval for the listing application of chemical raw materialsZhitong·Jul 28, 2025 at 04:02 AM603456+1.25%
Jiuzhou Pharma's subsidiary has obtained the drug registration certificate for sildenafil citrate orally disintegrating tabletsZhitong·Jul 1, 2025 at 03:09 AM603456+1.25%
Jiuzhou Pharma's subsidiary, Pharmaceutical Technology, passed the on-site inspection by the U.S. FDAZhitong·May 23, 2025 at 03:12 AM603456+1.25%
Jiuzhou Pharma completed the repurchase of 7.736 million shares at a cost of 102 million yuanZhitong·May 16, 2025 at 04:38 AM603456+1.25%
